Gilead Sciences, Inc. in 2 stories
The narratives GILD currently appears in, with its side and exposure in each.
Bull side
0 storiesNo bull-side stories for GILD yet.
Bear side
2 stories- America Imports the World's Drug Prices
GILD in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Gilead's patented HIV and oncology portfolio earns substantial US revenue and could suffer if lower foreign net prices anchor domestic reimbursement.
- The Patent Cliff Sparks a Biotech Land Grab
GILD in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Heavy dependence on HIV cash flows and uneven returns from past oncology acquisitions create pressure to replenish growth externally without overpaying.